Document is current

Any future updates will be listed below

The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

Crossref DOI link: https://doi.org/10.1186/s40545-016-0092-4

Published Online: 2016-12-30

Published Print: 2016-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark